INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS

The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, s...

Full description

Saved in:
Bibliographic Details
Main Authors QUEVEDO, Camilo, FALLON, Philip Spencer, PHILIPS, Simon, CRUZ, Abimael, TRAORE, Tenin, HOPKINS, Anna, RABBITTS, Terrence, WILLIAMS, Sophie Caroline, WINFIELD, Natalie Louise, LEE, Lydia Yuen-Wah
Format Patent
LanguageEnglish
French
German
Published 02.12.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
Bibliography:Application Number: EP20190702686